Background: Atrial fibrillation is associated with increased risks of death, stroke/systemic embolism, and bleeding (incurred by antithrombotic therapy), which may occur early after diagnosis. Methods: We assessed the risk of early events (death, stroke/systemic embolism, and major bleeding) over 12 months and their relation to the time after diagnosis of atrial fibrillation in 52 014 patients prospectively enrolled in the GARFIELD-AF registry (Global Anticoagulant Registry in the FIELD–Atrial Fibrillation) between March 2010 and August 2016. Results: Over 12 months, 2140 patients died (mortality rate, 4.3; 95% CI, 4.2–4.5 per 100 person-years), of whom 288 (13.5%) died in the first month (6.8; 95% CI, 6.1–7.6). Over 12 months, 657...
Aims The relationship between outcomes and time after diagnosis for patients with non-valvular atria...
Aims The relationship between outcomes and time after diagnosis for patients with non-valvular atria...
AIMS To determine the risk of subsequent adverse clinical outcomes in anticoagulated patients wit...
BACKGROUND: Atrial fibrillation is associated with increased risks of death, stroke/systemic embolis...
BACKGROUND: Atrial fibrillation is associated with increased risks of death, stroke/systemic embolis...
BACKGROUND: Atrial fibrillation is associated with increased risks of death, stroke/systemic embolis...
BACKGROUND: The factors influencing three major outcomes-death, stroke/systemic embolism (SE), and m...
BACKGROUND: The factors influencing three major outcomes-death, stroke/systemic embolism (SE), and m...
Background: Many patients with atrial fibrillation have concomitant coronary artery disease with or ...
BACKGROUND: Many patients with atrial fibrillation have concomitant coronary artery disease with or ...
© 2018, Pharmainfo Publications. All rights reserved. Background—Atrial fibrillation (AF) is the mos...
To assess the risk of death after the occurrence of different types of non-fatal events in patients ...
AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atri...
AIMS To determine the risk of subsequent adverse clinical outcomes in anticoagulated patients wit...
Aims The relationship between outcomes and time after diagnosis for patients with non-valvular atria...
Aims The relationship between outcomes and time after diagnosis for patients with non-valvular atria...
AIMS To determine the risk of subsequent adverse clinical outcomes in anticoagulated patients wit...
BACKGROUND: Atrial fibrillation is associated with increased risks of death, stroke/systemic embolis...
BACKGROUND: Atrial fibrillation is associated with increased risks of death, stroke/systemic embolis...
BACKGROUND: Atrial fibrillation is associated with increased risks of death, stroke/systemic embolis...
BACKGROUND: The factors influencing three major outcomes-death, stroke/systemic embolism (SE), and m...
BACKGROUND: The factors influencing three major outcomes-death, stroke/systemic embolism (SE), and m...
Background: Many patients with atrial fibrillation have concomitant coronary artery disease with or ...
BACKGROUND: Many patients with atrial fibrillation have concomitant coronary artery disease with or ...
© 2018, Pharmainfo Publications. All rights reserved. Background—Atrial fibrillation (AF) is the mos...
To assess the risk of death after the occurrence of different types of non-fatal events in patients ...
AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atri...
AIMS To determine the risk of subsequent adverse clinical outcomes in anticoagulated patients wit...
Aims The relationship between outcomes and time after diagnosis for patients with non-valvular atria...
Aims The relationship between outcomes and time after diagnosis for patients with non-valvular atria...
AIMS To determine the risk of subsequent adverse clinical outcomes in anticoagulated patients wit...